Review finds limited but positive evidence for grapiprant in dogs: full analysis

Version 2

A newly published evidence review is offering a measured answer to a common clinical question: does grapiprant reduce osteoarthritic pain in dogs? The review, published April 14, 2026 in Veterinary Evidence, concludes that grapiprant may improve pain-related daily function and orthopedic scores in dogs with osteoarthritis, but the available evidence is limited and inconsistent. After reviewing two randomized controlled trials, the authors rated the overall strength of evidence as weak. (veterinaryevidence.org)

That conclusion reflects the drug’s somewhat unusual evidence story. Grapiprant, sold as Galliprant, is a selective EP4 prostaglandin receptor antagonist rather than a traditional COX-inhibiting NSAID. The FDA approved it on March 20, 2016, for the control of pain and inflammation associated with osteoarthritis in dogs, and the approved label cites a placebo-controlled, masked field study in client-owned dogs with radiographic and clinical signs of OA. In that study, 285 dogs were enrolled for safety, 262 were evaluated for effectiveness, and treatment success was significantly higher with grapiprant than with placebo over 28 days. (dailymed.nlm.nih.gov)

The new Veterinary Evidence review centers on two trials with very different designs. In the chronic OA study, dogs receiving grapiprant showed significant improvement in owner-assessed outcomes, including treatment success, pain severity, and pain interference, along with veterinarian-assessed total orthopedic scores, compared with placebo. But the second study, which used an induced acute arthritis or synovitis model, did not find significant differences between grapiprant and control for vertical force ratios or visual lameness scores. The reviewers’ bottom line is that grapiprant may help with chronic osteoarthritic pain, but current data do not establish consistent efficacy across pain models. (veterinaryevidence.org)

That chronic-versus-acute split is not entirely new. A 2021 narrative review described grapiprant’s therapeutic profile as appearing better suited to chronic rather than acute pain. The same review noted that grapiprant had been approved by the FDA and EMA at a once-daily 2 mg/kg regimen, while also emphasizing that published evidence on pharmacology, safety, and real-world efficacy remained relatively limited compared with older NSAID classes. (pubmed.ncbi.nlm.nih.gov)

Safety remains part of the clinical conversation. According to the current DailyMed label, the most common treatment-related adverse reactions seen in field studies were diarrhea, vomiting, and inappetence. The label also describes dose-related changes in some clinical pathology values and notes that, in the pivotal effectiveness study, dogs underwent a 7-day washout from NSAIDs or other current OA therapies before enrollment. That matters when clinicians interpret the evidence, because trial conditions may not fully mirror multimodal OA management in practice. (dailymed.nlm.nih.gov)

Why it matters: For veterinarians, this review doesn’t overturn current use of grapiprant, but it does sharpen expectations. The best-supported claim is not that grapiprant works broadly for every arthritis presentation, but that it has evidence for improving some outcomes in dogs with chronic, naturally occurring OA. That distinction is useful when discussing goals with pet parents, especially for dogs that may need a tailored pain plan because of comorbidities, tolerability concerns, or prior NSAID experience. At the same time, the “weak” evidence rating is a cue to avoid overstating certainty and to monitor response closely rather than assuming classwide or universal benefit. (veterinaryevidence.org)

There also appears to be a broader evidence gap around comparative effectiveness. The review cites limited randomized evidence, and the field still needs more direct comparisons with other OA therapies, better long-term outcome data, and studies that reflect the multimodal regimens many primary care and specialty practices already use. That’s particularly relevant as canine OA management continues to evolve and as clinicians weigh how oral analgesics fit alongside weight management, rehabilitation, nutritional strategies, and other pharmaceutical options. This is an inference based on the small number of trials identified in the review and the narrow design of the approval studies. (veterinaryevidence.org)

What to watch: The next meaningful development would be stronger comparative and longitudinal research, especially studies that test grapiprant in real-world chronic OA populations over longer follow-up and against active comparators, not just placebo or acute induced-pain controls. (veterinaryevidence.org)